Peetz Christopher sold $2.9M of MIRM
Peetz Christopher (CHIEF EXECUTIVE OFFICER) sold 30,000 shares of Mirum Pharmaceuticals, Inc. (MIRM) at an average of $95.84 ($94.64–$99.66, $2.88M total) across 6 trades on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale adds a modest negative bias to MIRM's short‑term outlook but does not alter longer‑term fundamentals.
Market read
First‑report insider sale; modest relevance for traders monitoring insider activity.
What to watch
Potential upcoming clinical data releases that could offset the negative signal.
Background
Form 4 filings disclose insider transactions; a CEO sale is often monitored for signals.
Ticker impact
CEO Christopher Peetz sold 30,000 shares for $2.9M via a 10b5-1 plan, reducing his stake to 194,309 shares.
likely downward pressure as investors price in the insider sell.
A $2.9M sale by the chief executive is material enough to attract attention, but the amount is modest for a mid‑cap biotech, so impact is limited.
Market effects
May prompt scrutiny of other insider holdings in the biotech sector.
Limited to U.S. biotech investors.
Minimal global effect.
Counterpoint
The sale could be a routine liquidity move unrelated to company fundamentals.
Key entities
- CompanyMirum Pharmaceuticals, Inc.
Biotech firm listed on NASDAQ under MIRM.
- ExecutiveChristopher Peetz
Chief Executive Officer of Mirum Pharmaceuticals.
